8:30 am Check-In & Coffee

9:20 am Chair’s Opening Remarks

  • Bob Lutz Chief Scientific Officer, Iksuda Therapeutics

Revolutionising ADC Design: Exploring Innovations & Strategies With Enhanced Therapeutic Efficacy

9:30 am Revisiting the Dogma of Antibody Drug Conjugates: A Data-Driven Perspective

Synopsis

  • Understanding different types of linker instabilities and the potential implications of designing ADCs with overly stable linkers
  • Questioning the ability of ADCs to deliver drugs exclusively to cancer cells while sparing normal cells
  • Analyzing ADC clinical data to establish correlations between efficacy, toxicities, and drug-linker technologies

10:00 am Versatile & Robust Chemical Site-Specific Conjugation Platform: AJICAP® Technology

Synopsis

  • AJICAP®️ Conjugation: Examining how site-specific technologies are being employed in many of the next-generation ADCs due to the enhancement of clinically relevant biological properties observed in various preclinical studies
  • AJICAP®️ Linker: Demonstrating a novel hydrophilic linker technology that enables the versatile synthesis of homogenous DAR = 1, 2, 4, 8, and higher
  • Showcasing Bispecific and Trispecific antibodies produced by fully-chemical conjugation technology

10:30 am Novel MMAU Auristatin Glycoside ADC Against Melanoma – Stabilised Hydrophilic Linker-Payload Provides A Wide Therapeutic Window & Improved Potency

Synopsis

  • Review novel auristatin ADCs based on MMAU payload enable widening of therapeutic window compared to vedotin ADCs
  • Discuss how high systemic and metabolic stability of cleavable glycopeptide linker improved both in vivo efficacy and tolerability
  • Assess DAR4 and DAR8 MMAU ADCs against solid and heme malignancies

11:00 am Technology Slam & Morning Networking

Synopsis

As you enjoy your afternoon refreshments, you will also have the chance to be face-to-face with the field’s most innovative and exciting technology providers. Join our dedicated technology slam to identify your next technology provider and progress your antibody-drug conjugate pipeline smoothly and efficiently

Track 1: Discovery Chemistry

Discovery Chemistry

Chair: Lolke de Haan, Chief Medical Officer, ADC Therapeutics

The Next Era of ADC Formats: Cashing In on ADC Precision & Turbocharging Therapeutic Efficacy

Download the Full Event Guide for full details


12:00 The Discovery of a New Degrader Antibody Conjugate (DAC)

Stephanie Monson, Principal Scientist, Genentech


12:30 Molecular Evolution of OncoFAP for the Tumor-Targeted Delivery of Biocidal Radionuclides & Cytotoxic Payloads

Andrea Galbiati, Senior Scientist, Philochem

Track 2: Translational
Track 3: Clinical Lessons
Track 4: Process & Analytical Development
Track 5: Manufacturing & Supply Chain

1:00 pm Lunch & Learn With Merck

Track 1: Discovery Chemistry

Discovery Chemistry

Next-Generation Approaches to Target Selection: Advancing ADC Precision for Improved Delivery & Reduced Toxicity

Download the Full Event Guide for full details


2:00 Oxford Biotherapeutics’ OGAP Target Discovery Platform: Use of Quantitative Membrane Tissue Proteomics to Identify new ADC Drug Target

Benjamin Thomas, Senior Director - USA & UK External Innovation Operations, Oxford Biotherapeutics


2:30 Drug Conjugates Targeting HER2 & HER3, Based On Engineered Affibody Molecules

Torbjorn Graslund, Associate Professor, KTH Royal Institute of Technology


3:00 End of Discovery Stream

Track 2: Translational
Track 3: Clinical Lessons
Track 4: Process & Analytical Development

3:30 pm Afternoon Break & Networking

Exploring The ADC Commercial Landscape: Insights & Perspectives for Market Success

4:00 pm Panel Discussion: Partnerships & Collaborations: Leveraging Alliances for ADC Market Success

  • Kurt Pike Senior Director, External Innovation, The Janssen Pharmaceutical Companies of Johnson & Johnson
  • John Zhu Chief Executive Officer, Duality Bio
  • Greg Dwyer Vice President and Head Of Business Development, Orum Therapeutics

Synopsis

  • Exploring the value of forming partnerships to accelerate ADC development, leveraging expertise and resources
  • Discussing how collaborations can facilitate market penetration, regional expansion, and increased patient access to ADC therapies
  • Sharing risks and rewards – highlighting the benefits of sharing costs, risks, and intellectual property in ADC partnerships, leading to mutual success in a competitive landscape

5:00 pm Licensing Boom: The Dynamic Ecosystem of ADC Industry

  • John Zhu Chief Executive Officer, Duality Bio

Synopsis

  • Unveiling key trends of collaboration in ADC industry
  • What’s behind the landmark collaborations between DualityBio and various partners?
  • Evaluate how the ecosystem and collaborations in ADC industry will evolve in the future

5:30 pm Chair’s Closing Remarks

  • Bob Lutz Chief Scientific Officer, Iksuda Therapeutics

5:35 pm End of Scientific Programme Day Two